Tianjin Chase Sun Pharmaceutical Co. Ltd was founded in 1996 and listed on the Shenzhen Stock Exchange in the year 2009锛圫tock code: 300026). In 2013, win top 20 of the most competitive pharmaceutical listed Company in China, and the top 10 management team award of 2013 Chinese GEM Listing Corporation. Chase sun pharma have GMP for Bulk drug (Fasudil hydrochloride, LMW Heparies calcium et.,) , as well as Capsules, Granules, Xuebijing Injection (Modern Traditonal Chinese Medicine); Technology transfer center of Chase Sun Pharma covers an area of 25,000 square meters with a total investment of 300 million Yuan (about fifty million USD). Technology transfer center possesses production lines for synthetic drugs, such a polusaccharide, peptides, anti-cancer drugs and production lines for large volume injection, small volume injection, freeze-dried powder and oral solid preparation. Each line is constructed in accordance with the GMP Standard (2010 revision) and has a laboratory for comprehensive testing and analysis with a complete production quality control system. Technology transfer center is committed to providing the customers services of process development of APIs and the intermediates from pre-clinical to the industrialization.
Following are our product list;
Product Name CAS NO. Application
Fasudil hydrochloride 锕� 105628-07-7 API for treating pulmonary hypertension
Fondaparinux Sodium 114870-03-0 API for Vascular diaseses
Fondaparinux Sodium intermediate N3 114903-05-8 Fondaparinux Intermeidate
Fondaparinux Sodium intermediate N4 N/A
Pramipexole dihydrochloride 104632-25-9 API for parkinson
(6S)-2-Amino-6-propionamidotetrahydrobenzothiazole 106006-84-2 Pramipexole intermediate
Clopidogrel hydrogen sulfate 135046-48-9 API for Cardiovascular and cerebrovascular disease
Clopidogrel Hydrochloride N/A API for Cardiovascular and cerebrovascular disease
2-(2-thienyl)ethyl toluene-p-sulphonate 40412-06-4 Clopidogrel intermediate
S-(+)-Methyl-(2-chlorophenyl)[(2-(2-thienyl)amino] acetate hydrochloride 141109-19-5
Clopidogrel camphorsulfonate 120202-68-8
Ibandronate sodium monohydrate 138926-19-9 API for malignant hypercalcemia
N-methyl-N-pentyl-beta-alanine methyl ester 744266-99-7 Ibandronate intermediate
3-(N-Methylpentylamino)propionic acid hydrochloride 625120-81-2
Ambrisentan 177036-94-1 API, hypotensor
Benzenepropanoic acid,a-hydroxy-b-methoxy-b-phenyl-,(aS)- 178306-52-0 Ambrisentan intermediate
Rocuronium bromide 119302-91-9 API for Anaesthesia
Rocuronium bromide intermeidate (LK-8) 119302-24-8 Rocuronium INT.
Flupirtine Maleate 75507-68-5 API, acesodyne
N6-[(4-fluorophenyl)methyl]-3-nitropyridine-2,6-diamine 33400-49-6 Flupirtine Intermediate
Sarpogrelate Hydrochloride 135159-51-2 API for Cardiovascular diaseses
1-(Dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]-2-propanol hydrochloride 135261-74-4 Sarpogrelate Intermediate
Tirofiban hydrochloride monohydrate 150915-40-5 API for Cardiovascular and cerebrovascular disease
N-Butylsulfonyl-O-(4-(4-pyridinyl)butyl)-L-tyrosine 149490-61-9 Tirofiban Intermeidate
Moxifloxacin hydrochloride 186826-86-8 API, antibiotic
Davercin 55224-05-0 API, antibiotic
Erythromycin 114-07-8 Davercin Intermediate
Thymalfasin 69440-99-9 API, Immunomodulator
Thymalfasin intermediate N/A Thymalfasin intermediate
Roflumilast 162401-32-3 API for COPD
Nadroparin calcium N/A API for treating pulmonary hypertension
锕� GMP锛� Products covered by valid patents are not offered or supplied for commercial use in those countries.The intermediates, impurities of all above APIs are available upon request.
|
